Diabetes Drug Development Drug Pricing 
STAT
JUNE 26, 2023
government agency on Tuesday said that it won’t recommend Eli Lilly’s Mounjaro — part of a new class of medications that help patients lose weight — for people with type 2 diabetes without additional evidence. LONDON — A U.K. Mounjaro, also known as tirzepatide, has U.S.
STAT
SEPTEMBER 13, 2024
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning, and congratulations on making it through another week. She is very likely the cutest and most relatable animal I’ve ever seen.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
STAT
OCTOBER 17, 2024
billion deal in which Novo Nordisk’s parent foundation would acquire Catalent, a leading contract drug manufacturer, over concerns the acquisition will harm competition and reduce patient access to popular diabetes and weight loss medicines.
STAT
JUNE 24, 2024
On top of today’s Alnylam news, we have Congress gearing up to vote on Medicare coverage for multi-cancer screenings and obesity drug coverage. Also, updates on Vertex’s type 1 diabetes cell therapy, and a push for phage therapy. Read the rest…
STAT
JUNE 20, 2024
With the immense demand for GLP-1-based drugs and recurring shortages of the branded treatments, a wide variety of businesses have popped up to offer their own versions of what they claim are GLP-1 drugs. No other company has bid on the contract — to supply 14 million pens for the next three years, at about $2 per pen. The
STAT
APRIL 12, 2024
Enjoy, and see you soon… Western drug makers are talking to alternative suppliers in response to draft U.S. legislation seeking to restrict an important Chinese drug developer and manufacturer over national security concerns , The Financial Times explains. But be safe. The Biosecure Act would prohibit U.S.
STAT
JULY 17, 2024
Patients on insulin fear the GLP-1 gold rush is leaving them behind As Novo Nordisk and Eli Lilly invest billions to scale up manufacturing capacity for their highly profitable GLP-1 drugs, diabetes patients around the world are suddenly facing shortages of various insulin products. Read the rest…
Expert insights. Personalized for you.
258 
Let's personalize your content